LearnGlossaryMarketStocksSuperinvestorsSign in

RXRX

Recursion Pharmaceuticals, Inc.

Healthcare · $1.7B market cap

Verdict

We can't put a fair value on RXRX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth1.6% a year✗
Sales growth32.3% a year✓
Free cash flow growth—?
Return on invested capital-48.8%✗

Follow RXRX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 1, 2026: no open-market purchases and 2 sales worth $179K. Why purchases matter

Sales

Khan Najat

CEO and President · 2026-09-08

Sold

$79K

Borgeson Blake

director · 2026-09-01

Sold

$100K

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works